阐明离子液体诱导的GH1β-葡萄糖酶的混合抑制 H0HC94
Bharat Manna1, Pinaki Chanda1, Supratim Datta1,2,3
1Protein Engineering Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal741246, India.
The journal of physical chemistry. B
|September 26, 2023
概括
离子液 (ILs) 根据度不同抑制β-葡萄糖酶. 较低的IL水平会导致竞争性抑制,而较高的水平会通过改变酶结构来诱导混合类型的抑制.
科学领域:
- 生物化学 生物化学
- 酶动力学 酶动力学
- 计算化学是一种计算化学.
背景情况:
- 在可发酵糖合成的"一"工艺中提高甘酸酶 (GH) 效率,需要了解离子液 (IL) 耐受性.
- 通过1-乙基-3-甲基利米达酸盐 ([C2C1im][MeCO2]) 来抑制来自*Agrobacterium tumefaciens* 5A的GH1β-葡萄糖酶 (H0HC94) 对生物炼油应用提出了挑战.
研究的目的:
- 研究离子液[C2C1im][MeCO2]对GH1β-葡萄糖酶 (H0HC94) 的度依赖抑制.
- 通过实验和理论方法阐明竞争和混合类型抑制的基础机制.
- 为开发IL耐受性β-葡萄糖酶提供洞察力,用于增强生物炼油工艺.
主要方法:
- 进行了实验性酶动力学测试,以确定抑制模式和常量.
- 使用Lineweaver-Burk图形来描述抑制类型.
- 进行了原子分子动力学模拟,以可视化不同度的IL与酶的相互作用.
- 自由能量景观和蛋白质结构网络的主要组件分析 (PCA) 分析了结构变化.
主要成果:
- 在10-15%的[C2C1im][MeCO2]中,H0HC94表现出竞争性抑制 (R2 = 0.97,α = 2.8).
- 在20-25%的[C2C1im][MeCO2]下,抑制转向混合型 (R2 = 0.98,α = 3.4).
- 分子动力学模拟显示,在较低的IL度下,活性部位的阴离子积累,与竞争性抑制相一致.
- 在较高的IL度下,阳离子和阳离子都与二次结合位 (SBS) 结合,诱导三级形状变化和混合型抑制.
结论:
- 这项研究为ILs对GH1β-葡萄糖酶的混合抑制提供了第一个结合实验和理论解释.
- 二次结合位点 (SBS) 在IL诱导的酶抑制中起着至关重要的作用.
- 了解这些机制可以指导IL耐受β-葡萄糖酶的工程,以提高生物炼油效率.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
Enzyme Inhibition
78.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.6K
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Acid Halides to Ketones: Gilman Reagent
2.9K
Lithium dialkyl cuprate, also known as Gilman reagents, selectively reduces acid halides to ketones. The acid chloride is treated with Gilman reagent at −78 °C in the presence of ether solution to produce a ketone in good yield.
As shown below, the mechanism proceeds in two steps. First, one of the alkyl groups of the reagent acts as a nucleophile and attacks the acyl carbon of the acid chloride to form a tetrahedral intermediate. This is followed by the reformation of the carbon–oxygen...
As shown below, the mechanism proceeds in two steps. First, one of the alkyl groups of the reagent acts as a nucleophile and attacks the acyl carbon of the acid chloride to form a tetrahedral intermediate. This is followed by the reformation of the carbon–oxygen...
2.9K


